Hims & Hers Health, Inc. (HIMS) is a leading telehealth company that provides prescription drugs, over-the-counter products, and health counseling via its platform. In Q1 2025, HIMS posted stunning financial results: revenue grew 111% year-over-year, with subscriber counts and profitability both rising sharply. At the same time, President Trump signed executive orders in April and May 2025 aimed at lowering US prescription drug prices by linking them to those in developed countries. These policies could have profound effects on HIMS's operations and financial performance. This article combines HIMS's latest earnings data with Trump's drug pricing initiatives to analyze the company's financial health, growth prospects, and the opportunities and challenges posed by the policy.
HIMS Q1 2025 Financial Performance Overview
HIMS delivered strong financial results in Q1 2025. Key metrics are summarized below:
Revenue and User Growth
Revenue grew from USD 278.2 million in Q1 2024 to USD 586 million in Q1 2025, up 111% YoY.
This growth was driven by:
- Subscriber growth: Subscribers increased from 1.709 million to 2.4 million, up 38%, reflecting success in attracting new users.
-
Higher revenue per user: Average monthly online revenue per subscriber rose from USD 55 to USD 84, up 53%, indicating that HIMS is boosting user value through personalized services and premium products.
-
Business expansion: HIMS launched new services in weight loss, cardiovascular health, and mental health. The weight loss business alone is expected to contribute USD 725 million in revenue in 2025.
Profitability and Cash Flow
Profitability improved significantly. Net income rose from USD 11.1 million to USD 49.5 million, and adjusted EBITDA increased from USD 32.3 million to USD 91.1 million. The expansion of adjusted EBITDA margin was driven by leverage in marketing and administrative expenses, which improved by approximately 800 bps and 400 bps, respectively.
Additionally, the company reported USD 50.1 million in free cash flow, up sharply from USD 11.9 million in Q1 2024, demonstrating strong cash generation.
Gross Margin Change
Despite strong financial performance, gross margin fell from 82% in Q1 2024 to 73%. This decline likely reflects:
-
Business mix shift: Increased investment in new businesses like weight loss, which may have different cost structures than legacy offerings.
-
Growth investments: Spending on facilities, technology (e.g., AI and MedMatch), and partnerships (e.g., with Novo Nordisk) may have temporarily raised costs.
2025 and Long-Term Outlook
HIMS is optimistic about 2025, providing the following guidance:
-
Full-year 2025: Revenue expected between USD 2.3 billion and USD 2.4 billion; adjusted EBITDA between USD 295 million and USD 335 million.
-
Q2 2025: Revenue expected between USD 530 million and USD 550 million; adjusted EBITDA between USD 65 million and USD 75 million.
-
2030 target: HIMS expects to achieve at least USD 6.5 billion in revenue and USD 1.3 billion in adjusted EBITDA by 2030, signaling confidence in long-term growth.
Background of Trump's Drug Price Reduction Policies
In April and May 2025, Trump signed several executive orders aimed at lowering US prescription drug prices. Key policies include:
-
Most-favored-nation pricing: Tying US drug prices to those in developed countries (e.g., Canada, European nations), targeting reductions of 59% to 90% for certain drugs (Reuters).
-
Enhanced Medicare negotiation: Strengthening the Medicare drug price negotiation program, aiming for savings beyond the first year's 22%.
-
Direct-to-consumer sales: Directing HHS Secretary Robert F. Kennedy Jr. to establish a mechanism allowing patients to buy drugs directly from manufacturers at "most-favored-nation" prices, bypassing middlemen.
-
Focus on weight loss drugs: Trump specifically mentioned weight loss drugs as a target for price cuts, directly impacting HIMS's weight loss business.
These policies aim to address the fact that US consumers pay far more for drugs than people in other countries. However, the pharmaceutical industry opposes them, arguing the measures may be difficult to implement and lack clear legal authority (New York Times).
Potential Impact of Trump's Drug Price Policies on HIMS
As a telehealth company offering prescription drugs (e.g., weight loss and erectile dysfunction treatments) and health counseling, HIMS could be affected in several ways:
1. Lower Drug Procurement Costs
If Trump's policies succeed in reducing prescription drug prices, HIMS may source drugs at lower costs. This would reduce its cost of goods sold (COGS), potentially improving gross margins. Given that HIMS's gross margin has already fallen from 82% to 73%, cost relief could help ease margin pressure.
2. Increased Demand
Lower drug prices could make treatments more affordable, boosting demand for HIMS's telehealth services. HIMS's subscription model and convenient online platform position it well to attract price-sensitive consumers. In particular, its weight loss business could benefit from cheaper drugs, as consumers may be more willing to try these treatments.
3. Challenges for Compounded Drugs
HIMS offers compounded weight loss drugs (e.g., generic versions of Novo Nordisk's Wegovy), which are popular due to lower prices. However, Trump's policies could reduce demand for compounded drugs if brand-name drugs become cheaper, eroding the cost advantage of compounded alternatives. Additionally, in February 2025, the FDA declared the shortage of Novo Nordisk's weight loss drugs over, leading HIMS to warn that its compounded drug supply could be limited, causing its stock to drop 27% (Reuters). Trump's policies may exacerbate this pressure.
4. Regulatory and Pricing Pressure
Trump's executive orders could trigger new regulations affecting telehealth and compounded drug operations. HIMS may need to adjust its pricing strategy to remain competitive, especially in high-growth areas like weight loss. Moreover, if policies intensify competition, HIMS could face pressure from other telehealth providers.
5. Impact on Insurance and Customer Base
Trump's policies specifically mention drugs covered by Medicare, Medicaid, and private insurance. HIMS's core customer base is younger consumers who may rely less on Medicare. However, overall lower drug prices could indirectly make HIMS's services more attractive.
HIMS's Strategic Response and Competitive Advantages
HIMS's business model relies not only on drug sales but also on telehealth consultations, personalized care, and over-the-counter products. This diversification helps mitigate risks from drug price changes. Key strategic advantages include:
-
Personalized services: HIMS uses AI and MedMatch technology to offer customized treatment plans, enhancing customer stickiness. In Q1 2025, 30% of customers chose personalized treatment options.
-
Efficient operations: HIMS boasts strong unit economics, with customer acquisition cost payback in under a year and long-term retention rates above 85%, supporting profitability in a competitive market.
-
Business expansion: Expansion into weight loss, cardiovascular, and mental health provides diversified revenue streams, reducing the impact of any single policy change.
-
Technology investments: Investments in facilities and technology (e.g., lab diagnostics and partnerships with Novo Nordisk) enhance service capabilities and help navigate regulatory changes.
Risks and Uncertainties
Despite HIMS's strong financial performance and strategic positioning, Trump's drug price policies introduce uncertainties:
-
Policy implementation uncertainty: Analysts and legal experts question the enforceability of the executive orders, citing a lack of clear legal authority (Reuters). If policies are not effectively implemented, HIMS may not see the expected cost or demand changes.
-
Compounded drug regulation: HIMS's weight loss business relies on compounded drugs. Any further regulatory restrictions could threaten its USD 725 million revenue target.
-
Market reaction: Due to the lack of specific data on HIMS's stock price reaction to the May 2025 executive orders, it is difficult to accurately assess market sentiment. However, the stock's 27% plunge in February 2025 following compounded drug restrictions shows that investors are highly sensitive to HIMS's weight loss business.
Conclusion
Hims & Hers Health, Inc. delivered outstanding financial results in Q1 2025, with revenue up 111% and strong growth in subscribers and profitability. Trump's drug price reduction policies present potential opportunities for lower costs and increased demand, but also pose challenges for its compounded drug business and regulatory environment. With its diversified services, operational efficiency, and strategic investments in new businesses, HIMS is well-positioned to maintain a competitive edge in a changing healthcare landscape. Investors should closely monitor policy implementation and HIMS's adjustments in its weight loss and compounded drug strategies to assess long-term growth potential.
References
- Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results https://investors.hims.com/financials/quarterly-results/default.aspx
- Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results (Press Release) https://investors.hims.com/news/news-details/2025/Hims--Hers-Health-Inc--Reports-First-Quarter-2025-Financial-Results/
- Trump executive order demands pharma industry price cuts https://www.reuters.com/business/healthcare-pharmaceuticals/trump-says-he-will-cut-drug-prices-by-59-2025-05-12/
If you enjoyed this, stay tuned for more earnings analysis. Next up: space economy, focusing on a rocket services company.
Risk disclaimer: This content is for informational purposes only and does not constitute investment advice. Markets carry risk; invest wisely.
Like what you read? Follow for more!
